Logo of jester cap with thought bubble.

Image source: The Motley Fool.

SILK ROAD MEDICAL INC (NASDAQ:SILK)
Q3 2020 Earnings Call
Nov 10, 2020, 4:30 p.m. ET

Contents:

  • Prepared Remarks
  • Questions and Answers
  • Call Participants

Prepared Remarks:

Operator

Good afternoon, ladies and gentlemen, and welcome to the Silk Road Medical's 2020 Third Quarter Earnings. [Operator Instructions]. As a reminder, this conference call is being recorded.

I would now like to turn the conference over to your host, Ms. Caroline, Paul. Ma'am, please go ahead.

Caroline Paul -- Investor Relations

Thank you. And thank you all for participating in today's call. Joining me are Erica Rogers, Chief Executive Officer; and Lucas Buchanan, Chief Financial Officer and Chief Operating Officer. Earlier today, Silk Road Medical released financial results for the quarter ended September 30, 2020. A copy of the press release is available on the Company's website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements.

All forward-looking statements including without limitation those relating to our operating trends and future financial performance, the impact of COVID-19 on our business and prospects for recovery, expense management, expectations for hiring, physician training, growth in our organization and reimbursement market opportunity, guidance for revenue, gross margin, operating expenses, and 2020 commercial expansion, label expansion and product pipeline development are based upon our current estimates and various assumptions.

These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our quarterly report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2020. This conference call contains time sensitive information and is accurate only as of the live broadcast today November 10, 2020. Silk Road Medical disclaims any intention or obligation, except as required by law to update or revise any financial projections or forward-looking statements whether because of new information, future events or otherwise.

And with that I will turn the call over to Erica.

Erica J. Rogers -- President and Chief Executive Officer

Thanks, Caroline. Good afternoon, everyone, and thank you for joining us for Silk Road Medical's Third Quarter Earnings Call. Joining me is Lucas Buchanan, our Chief Financial Officer and Chief Operating Officer. Our third-quarter results are a testament to our team's steadfast commitment to stroke prevention and the underlying severity of carotid artery disease.

We achieved total revenues of $20.1 million, reflecting growth of 18% year-over-year. Our top-line performance was driven by 25% growth in procedures for a total of approximately 2,825 in the quarter. With these encouraging trends, we remain cautiously optimistic about the fourth quarter. Recognizing strength in procedure volumes and underlying demand, but also acknowledging the very recent trends and potential negative impact of the COVID-19 resurgence. That being said, we are incredibly proud to have recently crossed the 25,000 cumulative procedures milestone, a testament to our team's drive and the underlying market opportunity. Over the course of the year, we have been strengthening our ability to drive long-term growth. We are investing meaningfully in R&D initiatives, expansion of our commercial team and the recent launch of our new website featuring our Brighter Campaign. The future of Silk Road is indeed bright.

We are also positioning our leadership and organizational structure for growth ahead. As we announced earlier in the year, Andy Davis is spearheading our commercial efforts in the newly created position of Chief Commercial Officer. Andy continues to have a monumental role in our commercial success by driving safe adoption of TCAR across the United States, while gearing up for future label expansions, product launches and international strategies.

We are also pleased to have announced Bill Whalen, as our Executive Vice President of R&D. Bill brings two decades of scientific and development leadership to Silk Road, where he is responsible for advancing our pipeline and expanding our intellectual property portfolio. Bill has a passion for identifying and solving unmet clinical needs and a proven track record leading innovative R&D teams. He will be instrumental to our growth both today and tomorrow.

And finally, I am excited about the promotion of Lucas Buchanan, who now has an expanded role as our Chief Operating Officer in addition to Chief Financial Officer. Lucas's deep knowledge of our business and strong leadership skills make him the ideal COO, as we scale our organization and pursue new strategic initiatives while maintaining operational excellence.

Turning now to the three strategic initiatives for 2020 that we outlined at the beginning of the year, we are making significant progress on all three. US commercial execution, developing our strategy for label expansion and coverage for the standard surgical-risk patient population and further pipeline development.

Starting first with US commercial execution, we remain focused on our large untapped market opportunity to drive TCAR penetration in high surgical risk patients through increased physician utilization, while expanding our base of sales territories, hospital accounts and trained physicians. We have continued to add to our talented commercial team and remain on track to end 2020 with 40 to 45 active territories. Our team has also done an excellent job training physicians in new and innovative ways that adjust to the realities of the COVID-19 environment. After the dip in training in Q2 that we talked about on last quarter's call, we have successfully pivoted to new methods and we are quite pleased with our training progress in the third quarter. Demand for TCAR training remains strong. As further validation of our platform, we are also honored by the recent peer-reviewed publication of the ongoing TCAR Surveillance Project in Annals of Surgery in September and our ROADSTER 2 Study in the American Heart Association's journal Stroke this past July.

These datasets in high impact factor journals enable the benefits of TCAR to reach a broad base of referring and treating physicians across the stroke care continuum and further validate our ever-growing clinical evidence base as it reaches payers, regulators, medical societies and other critical stakeholders. Collectively, these papers represent over 7,000 patients worth of data published in just this quarter. In this business clinical data is a major tailwind for long-term growth.

And now shifting to our second key priority providing more clarity on the regulatory and reimbursement strategy for standard surgical risk patients. We continue to make meaningful progress on our ongoing discussions with key stakeholders, including the FDA. As previously disclosed, we have been targeting the end of this year to discuss our strategy in this area in more detail. While nothing substantial has changed in the assessment of our strategy, the process of working through it with the FDA, CMS, and the Society of Vascular Surgery is simply taking more time. As a result disclosure of our strategy is likely to occur after the end of the year. Our goal, all along has been to reach an optimal path forward to obtain not just expanded FDA label but also Medicare coverage and ultimately adoption, and we remain on that path.

Finally, our third strategic priority is focused on continued pipeline development. We consider ourselves experts and TransCarotid access and neuroprotection and we have made meaningful progress on product development, not just for TCAR but also in acute ischemic stroke. We are expecting to move into clinical and regulatory activities for our neurovascular program next year. While much has been achieved in acute stroke thrombectomy in recent years, significant unmet needs remain in terms of patient outcomes and we are excited about the potential for TransCarotid therapies to usher in a new paradigm.

In summary, we are continuing with our progress on our long-term initiatives, and we believe our opportunities in stroke prevention and acute stroke treatment are brighter than ever.

With that, I will now turn the call over to Lucas to review our financials in more detail.

Lucas Buchanan -- Chief Financial Officer and Chief Operating Officer

Thank you, Erica. Revenue for the three months ended September 30, 2020, was $20.1 million, an 18% increase from $17.0 million in the same period of the prior year. Growth was again driven by increased adoption of TCAR across an expanded base of hospital accounts, trained physicians and active sales territories, partially offset by regional headwinds related to COVID-19. There were approximately 2,825 TCAR procedures performed in the third quarter of 2020 representing a 25% increase compared to the same prior-year period.

Gross margin for the third quarter of 2020 was 73% as compared to 76% in the corresponding prior-year period. The gross margin decline was due to unfavorable production variances, as a result of temporarily idled manufacturing operations early in the quarter related to COVID-19, as well as the timing of certain manufacturing engineering projects. Total operating expenses for the third quarter of 2020 were $23.9 million, an 18% increase from $20.3 million in the third quarter of 2019.

R&D expenses for the third quarter of 2020 were $4.7 million compared to $3.2 million in the third quarter of 2019. The increase was driven by an increase in personnel-related expenses and product development initiatives. Sales, general and administrative expenses for the third quarter of 2020 were $19.2 million compared to $17.1 million in the third quarter of 2019.

The increase was primarily attributable to expenses related to growth in our commercial team and personnel-related expenses. Expense growth was partially offset by the continued reduction in travel, trade show and other expenses due to COVID-19. Net loss for the period was $10.3 million or a loss of $0.31 per share, as compared to a net loss of $8 million or a loss of $0.26 per share for the same period of the prior year. We ended the third quarter of 2020 with $153.9 million of cash, cash equivalents and short-term investments. To further strengthen our balance sheet and cash flow, on October 29, we successfully refinanced our long-term debt at a significantly lower cost of capital with a new $50 million loan facility. As we approach the end of the year, we would like to provide some additional commentary on our strategic priority of US commercial execution with the caveat that COVID-19 resurgence could impact our ability to achieve these.

We currently have 40 active sales territories and expect to begin 2021 with 43. As it relates to physician training, we expect to have trained approximately 325 physicians by year-end, which would bring our total trained physician base to just over 1,770. As Erica mentioned, demand for training remains strong. Regarding our revenue outlook for the remainder of the year, we are cautiously optimistic as we continue to execute during the fourth quarter, but we want to be transparent about the difficulty estimating the impact of the pandemic on our near-term financial results.

That said, our team is resilient, our balance sheet is strong and our therapy delivers value, which positions us well as we close out the year and look forward to 2021.

At this point, I would like to turn the call back to Erica for closing comments.

Erica J. Rogers -- President and Chief Executive Officer

In closing, we are well-positioned for continued growth, and we remain dedicated to meaningfully impacting both stroke prevention and acute stroke treatment. And in fact, we recently observed World Stroke Day on October 29. Every year, this provides an excellent opportunity to raise awareness of the serious nature and high rates stroke and the huge burden it places on over 40 million people worldwide, who are directly and indirectly affected by this catastrophic disease. This year is just as important as ever to highlight the prevalence of stroke and remind people not to delay their healthcare.

I want to thank all of our many partners for collaborating with us on this important cause. Our team is working alongside them on this journey to change the standard of care and improve patient lives with innovative technology. As we like to say at Silk Road delivering brighter patient outcomes through brighter clinical thinking.

At this point, I would like to open the call for questions.

Questions and Answers:

Operator

Thank you, ma'am. [Operator Instructions] Your first question is from Robbie Marcus from JPMorgan. Your line is open.

Robbie Marcus -- JPMorgan -- Analyst

Oh, great. Thanks for taking the question and congrats on a nice quarter. I'll just ask both my questions up front, you made two, let's call, incremental new announcements on the call here. One about the new stroke -- ischemic stroke pipeline product, the other about the strategy for standard risk. Maybe you could address them separately. First, there is a lot of ischemic stroke products out there. I've always viewed TCAR as a delivery system. Do we look at this as a delivery system for an existing ischemic stroke product or do we think about this as a totally independent new product of your own?

And then second on the standard risk approval pathway. Maybe you could give us a little flavor for what's causing the delay, is it COVID or otherwise? And what's the chance? We still need a new trial from start to finish to get that thanks a lot?

Erica J. Rogers -- President and Chief Executive Officer

Hi, Robbie, thanks very much for the question. Good to hear from you today. Let me take those in the order, they were asked. Let's talk about our initiatives in acute ischemic stroke first. So I think it starts by saying we're taking a very differentiated approach to what is available in the market today, Robbie. And as you well know, and as you pointed out, it's a very competitive space, and therefore, we believe it's not in our best interest to disclose all of the details, right now. There will become a point in time where it makes more sense to talk about the products, very specifically.

But I will say this, which is we've always been a company dedicated to improving outcomes and when we look at the statistics on the outcomes from acute stroke thrombectomy and find less than half of the patients do well. In other words, can live independently after a procedure. We see that as an opportunity for innovation and for improvement. And so I think it's safe to say, our approach is quite differentiated and will be aimed at outcomes.

On the second part of your question on standard risk, really nothing substantive has changed, Robbie. It's simply a matter of time. This just took more time than we had all hoped and that's in part due to the fact that we're working with a multi-headed partnership here with the Society of Vascular Surgery and the FDA really at the head of all of that. And while these entities have been very forthright and forthcoming in their assistance in this project throughout the year, I think it's safe to say there were some distractions around the table, they don't necessarily always make Silk Road their very first priority. And so while nothing substantive has changed. We feel good about the path that we're on, as we were in the last call, we just need some more time.

Robbie Marcus -- JPMorgan -- Analyst

Great. And maybe just to clarify on the stroke product because the TCAR system right now uses Cordis stent, is the -- whatever device that's going to be used for ischemic stroke, can you say if that's a third-party product or will it be an all-inclusive in-house product? Thanks.

Erica J. Rogers -- President and Chief Executive Officer

Yes, I I think at this point we're not really disclosing any of the details, but I will say that Silk Road has been, as disclosed in our S1, Robbie, way back in the day, has been working on products in this area for some time and we've really spent this last year honing our internal efforts.

Robbie Marcus -- JPMorgan -- Analyst

Great. Thanks for the questions.

Erica J. Rogers -- President and Chief Executive Officer

Thanks, Robbie.

Operator

Your next question is from Joanne Wuensch from Citi. Your line is open.

Joanne Wuensch -- Citi -- Analyst

Good evening, everybody. Great to virtually tee up. Thank you for the update on standard risk and other products. Can we touch a little bit on international expansion and what you're thinking about there?

Erica J. Rogers -- President and Chief Executive Officer

Yes. Hi, Joanne, good to hear from you. Sure. We haven't disclosed anything on international in terms of the specific timing, other than to say we're first working on removing the regulatory barriers to entering certain markets. And throughout the year we've said, we're focused on regulatory processes in both China and Japan. Certainly, Andy's new role as Chief Commercial Officer, he has international responsibility now which is providing some additional focus, but for now, we're not reviewing the details of timing.

Joanne Wuensch -- Citi -- Analyst

Thank you. And then my second question has to do a little bit with I think about 2021 and I'm not asking for guidance, but what I'm trying to get my head around is how you think about training, the impact of a vaccine on your business? And in terms of any patients that maybe sort of in a watchful waiting state that are looking for that entry to come into the pool? Thanks.

Erica J. Rogers -- President and Chief Executive Officer

Yes, really interesting question, Joanne. We -- the news on the vaccine is obviously fairly new. I think we all knew it was coming eventually, and so I think it's hard to pinpoint exactly how that's going to change or not change patient behavior, physician behavior, hospital behavior all of that. I think it's safe to say that organizations like the American Heart Association, our physician partners, their hospitals they're all working really hard at patient education to make sure that patients don't defer their healthcare. Obviously, the restraints in our procedure volume in Q3, which I think is a good sign. The patients are doing what they need to do to get their healthcare.

As it relates to physician training. As we said in the prepared remarks, the demand for training remains high and we've been pleasantly surprised by that focus among our physicians who also have a lot of other things to be thinking about in this period, and I think we're really proud of our team who has completely pivoted and learned new and innovative ways to train that in many cases, maybe more efficient and better.

Joanne Wuensch -- Citi -- Analyst

Wonderful. Thank you.

Erica J. Rogers -- President and Chief Executive Officer

Thanks, Joanne.

Operator

Your next question is from Rick Wise of Stifel. Your line is open.

Dylan Haas -- Stifel -- Analyst

Hey, guys. This is actually Dylan on for Rick. I just had a question around the procedure number for the quarter, kind of seems to imply that the July through September procedures per month on average were similar, a little bit better than the rate in June, which is around 900 and I think that you said on the last call, July started off, maybe a little bit less than that. I just wanted to hear from you, any comments on sequential trends you saw within the quarter?

Lucas Buchanan -- Chief Financial Officer and Chief Operating Officer

Sure. I think as Q3, typically is, Dylan, absent a pandemic, it tends to be back-half loaded. And there was a little bit more noise in the quarter, but certainly, we saw a strong September as we did in Q3 of 2019. And so those -- that trend played out. And so as physicians and patients potentially took a break and vacations in the July and August time frame and some other seasonality and as the different good and bad amplitudes of various regional virus activity plays for it that we still had a very strong September.

Dylan Haas -- Stifel -- Analyst

Got it. Thank you. And so, had a question on the idea of moving docs further up the adoption curve and it felt like coming into this year that that was maybe an increasing focus with the number of docs that you already had trained not for lack of interest and demand for new doc training, but yet have a large base, it seems like you'd be spending more time and effort there. But it's always a bit challenging for us to kind of measure and get a sense of the progress there given new docs that dilute the procedures per quarter number and maybe COVID. So just anyway you could provide some color on the progress you're making on the adoption front, whether that be more docs moving into a bucket that are doing, say 50% or more procedures as TCAR, anyway, do you want to frame that?

Lucas Buchanan -- Chief Financial Officer and Chief Operating Officer

Sure. Well, there -- again, there's certainly more noise quarter-to-quarter of this year with the pandemic, but I think the shorter answer -- the short answer is, we continue to like the metrics we see. Q3 was a return to a lot of the analytics, we look at internally including procedures per doc per time period. Q3 was similar to Q1 in that regard. So a nice recovery back almost pre-COVID type metrics, even as we continued to dilute the denominator with our training activities in Q3.

So that's the good news and looking forward to 2021 and beyond, as we've always said, we've spent many years building a really concentrated footprint of a commercial team going after a concentrated group of docs and hospitals and what will be our driver of growth in the years to come is the adoption curve. So that is still very much the focus of the team, even though we continue to train new docs and add new accounts and add new sales territories.

The bias more and more over time is really focused on driving physician utilization and driving procedures in each individual physician's adoption curve. And so I think I think absent COVID overall and some of the different trends we've seen each quarter throughout the year. We're still on the right path, which is why we've continued to invest a kind of across the board, right, in the commercial team, and physician training events and product development to position ourselves well for the long haul. And so COVID never deterred us from that goal -- those goals, and we have the balance sheet to do that.

Dylan Haas -- Stifel -- Analyst

Great. Thanks for taking the questions, guys.

Lucas Buchanan -- Chief Financial Officer and Chief Operating Officer

Thank you.

Operator

Your next your next question is from Danielle Antalffy from SV8 Leerink. Your line is open.

Danielle Antalffy -- SV8 Leerink -- Analyst

Hey, good afternoon, everyone. Thanks so much for taking the questions. Congrats on a good quarter. I was just wondering if you could give any color on what's happening. If you have any visibility into the sort of new patient funnel coming into the system? And I don't know if the right way to look at that is sort of the mix of asymptomatic versus symptomatic and how that's shifted in sort of the early days of COVID or what -- and whether you can comment as you look at Q4, it feels like backlog has largely been worked down. And so all of the growth from here would likely be coming from new patients into the system and I didn't know if that was an accurate assessment or not?

Erica J. Rogers -- President and Chief Executive Officer

Hi, Danielle. I'm so glad you asked that question, it's a question that was on our minds as well recently. And so we actually looked at some recent data to try to get a sense of how many patients are kind of new patient visits versus kind of existing, already diagnosed kind of patient visits. And what we saw was what you would expect is this sort of big dip in new patients in that March, April, early May time frame, and then it was interesting to see how it flipped back to kind of -- and in that time frame, existing patients continued to come into their physician's offices, but albeit at a slower rate.

What we saw recently was that existing patients are strong and new patients are on the rebound. So at least across the board patient visits to the healthcare provider are going up in both categories, both as new patients and existing patients which we find to be encouraging. One of the other things that happens, of course, in our businesses is there is a fair amount of the business that is symptomatic, is typically about a third of our procedure volume and those patients tend to be kind of more urgent in nature and those continue to hop-in throughout this last quarter.

Danielle Antalffy -- SV8 Leerink -- Analyst

Got it. That's helpful. And then just another question, I know that was kind of anecdotal during COVID, but it's not like you saw a little bit of a shift in, at least in some centers to a higher percentage of TCAR procedures versus CEA given the shorter length of stay, predictability, safety et cetera. So I was just wondering if that shift has sort of continued and/or accelerated? Is there any trend that sort of been sustained as we've sort of been coming out on the other side of COVID not that were out on the other side yet, but anything of note there that you guys could point out that could be a more sustainable trend once COVID is hopefully done?

Erica J. Rogers -- President and Chief Executive Officer

Yes, it's a good question, Danielle. The -- of course of the data are lagging. So it's hard to answer that with anything that's kind of data-driven in nature, but we can tell you anecdotally that we hear more stories like the one we told at the last earnings call and the one before that, where physicians are choosing TCAR over its efficiencies. It's less burdensome, to the patient, to the hospital, to the system and patients have a higher probability of going home versus a step-down type facility and that's all good in the pandemic. So we continue to hear more stories like that, but we haven't put any numbers behind it yet.

Danielle Antalffy -- SV8 Leerink -- Analyst

Okay. Thanks so much.

Erica J. Rogers -- President and Chief Executive Officer

Thanks, Danielle.

Operator

Your next question is from Adam Maeder from Piper Sandler. Your line is open.

Adam Maeder -- Piper Sandler -- Analyst

Hi, good afternoon. Thanks for taking the questions and congrats on the quarter. I just wanted to ask about recent business trends, and apologies if I missed this in the prepared remarks, but it sounds like you saw good momentum exiting Q3, but just wanted to ask about recent volume trends for October and thus far in November, as we started to see COVID-19 case counts start to decline here, so just any details you can share there would be great? And then I had [Phonetic] a follow-up.

Lucas Buchanan -- Chief Financial Officer and Chief Operating Officer

Adam, I'll take that. We obviously didn't provide any specific Q4 guidance in the prior question, we said September was strong, October was similar a slight decline numerically on procedures. And as we sit here on Tuesday the 10th, the virus situation is obviously quite fluid with the news coming out of the Midwestern states, Utah state of emergency, things like that, those are real -- real-time COVID related effects that remain to be seen how it will affect the month of November and what will happen in December, which creates some of the uncertainty, even though we're fairly close to the end of the year. But the underlying business trends, absent those exogenous COVID factors and patient behavior remain very strong.

Adam Maeder -- Piper Sandler -- Analyst

Okay, that's helpful. Incremental color there, Lucas. I appreciate it. And just for the follow-up. I wanted to ask about the neurovascular update and I know you're keeping things a little bit close to the vest for competitive reasons, but just wanted to see if you could give any extra color around kind of regulatory pathway forward, plans to collect clinical evidence, is this a 510(k) or PMA pathway? Just any color that you could provide would be much appreciated. Thanks so much.

Erica J. Rogers -- President and Chief Executive Officer

Yes, Adam. I appreciate the question. But unfortunately, we're just really want to keep the cards close to the vest here, I think you follow this market I know and I know that you know it's highly competitive and there's kind of two ways competitors maintain their lead in this space. One is through speed and the other is through intellectual property, and we're working on both. So we're interested in kind of staying in stealth mode at the moment.

Adam Maeder -- Piper Sandler -- Analyst

Okay. Totally fair. Thanks, Erica.

Operator

Your next question is from Bob Hopkins of Bank of America. Your line is open.

Bob Hopkins -- Bank of America -- Analyst

Okay, thanks, and thanks for taking the questions. Good afternoon. I just wanted to follow up a little bit on the pipeline commentary you made and the standard risk part. And on the standard risk, I don't recall if you said this, but do you -- are you communicating at this point whether or not you'll need to run a new clinical trial for standard-risk or whether that's not likely to be required based on all the data you've gathered through other means? I guess, that's question one.

And then on the ischemic stroke side, it sounds like you're going to need to do some clinical work. So is it fair to say that this is -- from a commercial perspective, this is probably not 2021 or perhaps even 2022 opportunity for you? So I'll leave at that. Thank you.

Lucas Buchanan -- Chief Financial Officer and Chief Operating Officer

Hey, Bob, I'll take the second part of the question, and then hand standard risk back to Erica. But, no, you should not expect revenue associated with the neuro program in 2021, it's really R&D activities.

Erica J. Rogers -- President and Chief Executive Officer

Yes. And obviously, Bob, we're excited to talk about it because just in the last couple of years there have been multiple published papers looking at the safety and efficacy of transcarotid access for acute stroke and many of the authors have concluded that outcomes can be significantly improved in patients who are prohibitive or difficult transfemoral or other access. And so it's interesting that like TCAR -- TCAR was a grassroots effort among vascular surgeons looking for a better way to do things and we're seeing that happening, and so the same story is kind of playing out here. So we're very excited about what's coming ahead in stroke.

On standard risk, we have not talked about whether or not a trial is going to be required. And we're going to continue to hold comment on that, Bob, and will obviously provide an update as soon as it makes sense. What we've been trying to do all along is make sure that our partners, here the Society of Vascular Surgery, FDA, in particular, are really in lockstep with this strategy and we just don't want to get ahead of them, and that's in part kind of leading to us pushing this out a little bit here today.

Bob Hopkins -- Bank of America -- Analyst

Okay. And then one quick follow-up. I'm just curious on the stroke side, does your vascular surgeon customer base kind of treat acute stroke today or is this -- are you going to have to kind of develop relationships with the interventional nerve radiology and neurosurgery community that primarily does that today?

Erica J. Rogers -- President and Chief Executive Officer

Yes, it's interesting. You know, the short answer is, there are some vascular surgeons who were in the stroke continuum of care. As you can imagine, particularly in symptomatic carotid artery disease. That obviously, makes real sense, but I think it's safe to say that we haven't really disclosed the specifics and won't today just because we want to keep the cards close to the vest on what the plan is, but it will reveal itself in time.

Bob Hopkins -- Bank of America -- Analyst

Okay, I'll leave it at that. Thanks so much.

Erica J. Rogers -- President and Chief Executive Officer

Thank you, Bob.

Operator

I'm showing no further questions at this time. I would now like to turn the conference back to you Ms. Erica Rogers.

Erica J. Rogers -- President and Chief Executive Officer

Thank you very much, and thank you all for your questions and for listening in today. Have a good holiday season. Bye-bye.

Operator

[Operator Closing Remarks]

Duration: 37 minutes

Call participants:

Caroline Paul -- Investor Relations

Erica J. Rogers -- President and Chief Executive Officer

Lucas Buchanan -- Chief Financial Officer and Chief Operating Officer

Robbie Marcus -- JPMorgan -- Analyst

Joanne Wuensch -- Citi -- Analyst

Dylan Haas -- Stifel -- Analyst

Danielle Antalffy -- SV8 Leerink -- Analyst

Adam Maeder -- Piper Sandler -- Analyst

Bob Hopkins -- Bank of America -- Analyst

More SILK analysis

All earnings call transcripts

AlphaStreet Logo

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.